Roivant is a clinical-stage biopharmaceutical company that develops drugs for autoimmune and inflammatory diseases. The company uses a holding company model called the Vant structure, where it creates semi-independent subsidiaries to develop specific drug programs. While individual Vants manage day-to-day clinical execution, Roivant centrally handles capital allocation and business development. Roivant primarily builds its pipeline by in-licensing drug candidates from other pharmaceutical firms and advancing them through late-stage trials. Its core pipeline includes brepocitinib, an oral inhibitor for rare conditions like dermatomyositis, and IMVT-1402, a subcutaneous antibody for multiple autoimmune diseases including Graves' disease. The company is also developing mosliciguat, an inhaled treatment for pulmonary hypertension associated with interstitial lung disease. Additionally, Roivant operates Genevant, a platform that generates value through lipid nanoparticle delivery intellectual property and litigation. Roivant’s business model involves commercializing approved drugs through specialized sales forces or monetizing its subsidiaries by selling equity stakes or entire Vants to strategic buyers. The company’s strategy focuses on expanding indications for its current assets and acquiring new drug candidates to accelerate through its development and commercial infrastructure.